Mapi Pharma Ltd. (“Mapi” or the “Company”), a late-stage clinical biopharmaceutical company specializing in long-acting injectable therapies, today announced that management will participate in the ...
NESS ZIONA, Israel, April 16, 2026 (GLOBE NEWSWIRE)-- Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting ...
NESS ZIONA, Israel, May 04, 2026 (GLOBE NEWSWIRE)-- Mapi Pharma Ltd. (“Mapi” or the “Company”), a late-stage clinical biopharmaceutical company specializing in long-acting injectable therapies, today ...
Mylan to invest an additional $20M in Mapi Pharma in support of continued progress on Phase 3 clinical studies “Mapi Pharma and Mylan share a commitment to improve the lives of MS patients, and I am ...
The study evaluating a long-acting glatiramer acetate injection, GA Depot 40 mg once every four weeks, met the primary endpoint, significantly reducing the annualized relapse rate (ARR) by 30.1 ...
With the end of the year fast approaching, nations are looking for ways to secure enough supply of a potential COVID-19 vaccine to meet demand from their citizens. For Israeli drugmaker Mapi Pharma, ...
The MarketWatch News Department was not involved in the creation of this content. NESS ZIONA, Israel, April 16, 2026 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results